Compare · BNTX vs FENC
BNTX vs FENC
Side-by-side comparison of BioNTech SE (BNTX) and Fennec Pharmaceuticals Inc. (FENC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and FENC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $25.61B, about 60.8x FENC ($421.5M).
- Over the past year, BNTX is up 1.3% and FENC is up 34.3% - FENC leads by 33.1 points.
- FENC has been more active in the news (9 items in the past 4 weeks vs 6 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 5 for FENC).
- Company
- BioNTech SE
- Fennec Pharmaceuticals Inc.
- Price
- $101.92+0.35%
- $12.04-2.55%
- Market cap
- $25.61B
- $421.5M
- 1M return
- +10.50%
- +25.89%
- 1Y return
- +1.26%
- +34.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 5
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
- SEC Form 6-K filed by BioNTech SE
Latest FENC
- Former Director Raykov Rosty was granted 2,778 shares and sold $121,100 worth of shares (10,000 units at $12.11) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 124,411 units (SEC Form 4)
- Chief Medical Officer Sayad Pierre Sargis was granted 168 shares and sold $146,160 worth of shares (12,000 units at $12.18), decreasing direct ownership by 55% to 9,519 units (SEC Form 4)
- Chief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.79% to 21,519 units (SEC Form 4)
- Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.64% to 24,644 units (SEC Form 4)
- Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 66,302 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.71% to 241,306 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert sold $883,500 worth of shares (75,000 units at $11.78) as part of a pre-agreed trading plan and exercised 21,928 shares at a strike of $5.10, decreasing direct ownership by 18% to 239,603 units (SEC Form 4) (tax withholding)
- SEC Form 10-Q filed by Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026